AstraZeneca to Fight Medicare Drug Price Plan in Federal Court

A major drugmaker will argue Wednesday that the government price-setting program created to slash prescription drug costs was unlawfully implemented.

AstraZeneca PLC and the US Department of Justice will face off in the US District Court for the District of Delaware over the historic Medicare Drug Price Negotiation Program, which was formed under President Joe Biden’s 2022 Inflation Reduction Act to allow the government to set prices on some of the costliest drugs Medicare covers.

Among the nine ongoing lawsuits filed against the Biden administration, AstraZeneca’s approach to striking down the pricing scheme poses unique arguments compared to the ...